Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.59 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17507483 | 0.86 | TTR (0.55) | TTRALBPLA2G2ASMN1; SMN2MEN1 | |
| SCHEMBL17495595 | 0.83 | HSD17B10 (0.69) | TTRALBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17522782 | 0.81 | TTR (0.62) | TTRALBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10830829 | 0.80 | PLA2G2A (0.86) | PLA2G2AKMT2APLA2G4B | |
| SCHEMBL3077835 | 0.77 | PLA2G2A (0.80) | PLA2G2AKMT2APLA2G4B | |
| SCHEMBL17495600 | 0.75 | TTR (0.56) | TTRALBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL23352169 | 0.75 | PLA2G2A (0.96) | PLA2G2AKMT2APLA2G4B | |
| SCHEMBL28627609 | 0.75 | PLA2G2A (0.77) | PLA2G2AKMT2APLA2G4B | |
| SCHEMBL17522787 | 0.75 | SMN1; SMN2 (0.69) | TTRALBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10263820 | 0.74 | PLA2G2A (0.76) | PLA2G2AKMT2APLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172959-B2 | Systems for stabilizing and delivering active agents | Alhamadsheh, Mamoun M. (US) | 2019-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172959-B2 | Systems for stabilizing and delivering active agents | SERPINA6, SERPINC1, SERPINE1 | TTR 67/4885ALB 30/4885PLA2G2A 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.